TAVR is an Effective and Durable Treatment Modality for Symptomatic Aortic Insufficiency in LVAD Patients

Left ventricular assist devices (LVADs) revolutionized the management of patients with end stage heart failure (ESHF). Approximately 30% of patients develop aortic insufficiency (AI) after one year of LVAD support. AI is progressive and is associated with increased morbidity and mortality. Transcatheter aortic valve replacement (TAVR) is approved for treating symptomatic high surgical risk patients with severe aortic stenosis. TAVR is not studied in symptomatic AI in LVAD patients.